On February 15, 2022 Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment of cancer and fibrosis, reported that a clinical trial abstract describing the results of its Phase 1 clinical trial of AMP945 has been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meeting that will be held in New Orleans from April 8th to 13th 2022 (Press release, Amplia Therapeutics, FEB 15, 2022, View Source;[email protected] [SID1234608133]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract entitled "A Phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers" describes the results from Amplia’s Phase 1 clinical trial of AMP945 in healthy volunteers which completed in 2021. This trial showed that AMP945 was safe and well tolerated, could be administered orally once a day, and was able to inhibit its intended target, focal adhesion kinase (FAK), in tissue samples taken from participants in the study1. On the back of the successful data from this trial, Amplia intends to initiate a Phase 2 clinical trial in first line pancreatic cancer patients in early Q2 2022. This abstract will be presented at the AACR (Free AACR Whitepaper) Meeting in early April 2022 and also published online in the Proceedings of the AACR (Free AACR Whitepaper).

"The AACR (Free AACR Whitepaper) is one of the most recognised international forums for cancer research and we are delighted that the results of our Phase 1 trial have been selected for presentation at this prestigious meeting," said Dr. John Lambert, CEO of Amplia. "We believe the approach we are taking using AMP945 to potentially improve the current standard of care treatment for pancreatic cancer is well supported by our Phase 1 clinical trial data and the results from a number of nonclinical studies we have conducted."

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.